SG
INFI

Societe Generale’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Societe Generale’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$51K Buy
+38,353
New +$179K ﹤0.01% 2452

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Societe Generale's INFI Position: Q2 2016 in Review

Societe Generale opened a new position in Infinity Pharmaceuticals, Inc. (INFI) in Q2 2016: 38,353 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2452 among its holdings.

107 funds tracked by Wall St. Rank hold INFI as of Q2 2016.

  • Societe Generale held 38,353 shares of Infinity Pharmaceuticals, Inc. worth $51K as of Q2 2016.
  • Infinity Pharmaceuticals, Inc. was a new Societe Generale position in Q2 2016.
  • Infinity Pharmaceuticals, Inc. made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2452 holding.
  • 107 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.